L. Schlieker

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

J. Bergh, P. Neven, J. Crown, 2021, Breast cancer research : BCR.

Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE‐3)

V. Heinemann, J. Holch, T. Decker, 2021, International journal of cancer.

Midazolam microdosing applied in early clinical development for drug–drug interaction assessment

G. Mikus, M. Goettel, S. Wiebe, 2020, British journal of clinical pharmacology.

Abstract P6-21-01: Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results

J. Bergh, P. Neven, J. Cortes, 2019, Poster Session Abstracts.

Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

M. Climent, J. Bono, Chia‐Chi Lin, 2019, Journal of Clinical Oncology.

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

M. Climent, Chia‐Chi Lin, J. D. de Bono, 2023, British Journal of Cancer.